Vitiligo is an autoimmune skin condition in which the immune system mistakenly destroys melanocytes — the cells responsible for producing skin pigment (melanin) — creating well-defined white patches on the skin. It affects approximately 1-2% of the world's population equally across ethnicities, though it is more visually noticeable (and often more psychologically impactful) in people with darker skin. Vitiligo is not contagious, is not dangerous physically, and does not cause any systemic illness — but its psychological impact can be profound, particularly for children, adolescents and women. The condition can affect any body surface and may be associated with other autoimmune conditions (especially thyroid disease).

What treatments are available in 2024-2025?

Vitiligo treatment has been transformed since 2022: Topical ruxolitinib cream (Opzelura): first FDA-approved topical treatment for vitiligo; JAK1/2 inhibitor applied twice daily; approximately 30% achieve 75% facial repigmentation at 24 weeks; most effective on face. Narrowband UVB phototherapy: the most established treatment for widespread disease; twice-weekly sessions for 6-12 months; 50-75% repigmentation on eligible sites; requires phototherapy unit access. Topical calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus): off-label but evidence-based for localised facial vitiligo; safe for long-term use; no skin atrophy risk (unlike steroids). Excimer laser (308nm): for small localised areas; highly effective. Surgical transplantation (blister grafting, cellular melanocyte transplantation): for stable segmental vitiligo; 70-90% repigmentation; limited by availability and need for stable disease.

Vitiligo is not currently curable — treatment achieves repigmentation but does not permanently correct the underlying immune dysregulation, so relapse is possible when treatment stops. Key points about current treatment outcomes: Ruxolitinib cream needs to be continued to maintain repigmentation — stopping treatment leads to relapse in most patients over time. NB-UVB phototherapy can produce durable repigmentation that persists for months to years after stopping, particularly on the face. Surgical transplantation for segmental vitiligo can produce permanent repigmentation in areas that are fully stable (no new lesions). The development of more targeted immunomodulating treatments (oral JAK inhibitors, anti-IFN-γ therapies) may offer better long-term disease control in future.

What is the connection between vitiligo and other autoimmune diseases?

Non-segmental vitiligo is associated with multiple autoimmune conditions — particularly autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease, in approximately 15-20% of vitiligo patients), type 1 diabetes, alopecia areata, pernicious anaemia and Addison's disease. These associations reflect shared genetic variants in immune regulation pathways. Practical implications: all vitiligo patients should have annual thyroid function tests (TSH + thyroid antibodies); screening for other autoimmune conditions based on symptoms. The presence of multiple autoimmune conditions in one patient increases the likelihood of additional autoimmune comorbidities developing.

Why does vitiligo cause such psychological distress?

Vitiligo is a highly visible condition — and visibility, stigma and cultural context profoundly shape its psychological impact. Studies show vitiligo causes depression and anxiety in approximately 20-35% of patients, with Dermatology Life Quality Index (DLQI) scores comparable to severe psoriasis. Factors that worsen psychological impact: darker skin phototype (higher visual contrast); female sex; facial and acral involvement; childhood onset; cultural contexts where vitiligo is heavily stigmatised (particularly in South Asian countries where it can affect marriage prospects and social acceptance). Stigma historically included false associations with leprosy in some cultures. Psychological support, patient support groups, peer mentoring and cosmetic camouflage are important parts of comprehensive vitiligo management.

How does GMJ News cover vitiligo?

GMJ News covers ruxolitinib cream 2022 FDA approval (first topical), NB-UVB phototherapy, JAK-STAT pathway, segmental vs non-segmental disease, surgical transplantation, autoimmune associations (thyroid screening), psychological burden, Koebner phenomenon, differential diagnosis from pityriasis versicolor, and the melanocyte stem cell repigmentation biology. Vitiligo — affecting 1-2% of the population globally — is directly relevant to PHIG's dermatology programme and skin health equity agenda.

Home › Topics › Vitiligo

Vitiligo

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Vitiligo — an autoimmune condition in which CD8+ T-cells destroy melanocytes (pigment-producing cells) causing well-demarcated white patches on the skin — underwent a therapeutic revolution in 2022 when ruxolitinib cream 1.5% (Opzelura, Incyte) became the first FDA-approved topical treatment for non-segmental vitiligo — a condition that had essentially no evidence-based systematic treatment for decades, and the first topical Janus kinase (JAK) inhibitor approved for any condition — achieving meaningful repigmentation in approximately 30% of patients on the face at 24 weeks (TRuE-V trials) and transforming the therapeutic landscape for the approximately 1-2% of the global population affected, including children and adolescents for whom the psychological impact of visible depigmentation is particularly profound (WHO). Narrowband ultraviolet B (NB-UVB) phototherapy remains the most evidence-based treatment for widespread vitiligo, and the combination of NB-UVB with ruxolitinib is being actively investigated.

Key messages

Ruxolitinib cream — first approved topical vitiligo treatment (FDA 2022)

Ruxolitinib cream 1.5% (Opzelura, Incyte) — a topical JAK1/2 inhibitor — was FDA-approved July 2022 for non-segmental vitiligo in adults and adolescents ≥12 years. First approved topical treatment for vitiligo ever. TRuE-V trials: approximately 30% of patients achieved ≥75% improvement in facial vitiligo score (F-VASI75) at 24 weeks. Face responds better than acral sites.

Narrowband UVB — the most effective established treatment

Narrowband ultraviolet B (NB-UVB) phototherapy remains the most evidence-based treatment for widespread non-segmental vitiligo — with response rates of 50-75% repigmentation with twice-weekly sessions over 6-12 months. Can be combined with topical treatments. Requires phototherapy unit access — a significant barrier globally. Excimer laser (308nm) for localised vitiligo.

Autoimmune mechanism — IFN-γ and JAK-STAT pathway

Vitiligo is driven by CD8+ cytotoxic T-cells recognising melanocyte antigens → IFN-γ release → CXCL9/CXCL10 chemokines attracting more CD8+ T-cells (self-amplifying loop) → JAK-STAT signalling pathway (JAK1 and JAK2 are critical). This is why JAK inhibitors (ruxolitinib) are effective — blocking the CXCL10 feedback loop stops the immune attack on melanocytes.

Segmental vs non-segmental — different disease, different treatment

Non-segmental vitiligo (NSV, most common): bilateral, symmetric, progressive; associated with other autoimmune diseases; responds to topical/systemic immunosuppression and phototherapy. Segmental vitiligo (SV): unilateral, follows a dermatomal pattern, often starts in childhood, stable after initial rapid spread; associated with "mosaicism" theory; best treated by surgical melanocyte transplantation (blister grafting, cellular transplantation — highly effective in stable SV).

Psychological burden — equal to or exceeding many serious medical conditions

Vitiligo causes profound psychological impact — particularly in darker skin types where contrast is most visible, in women, and in adolescents. Vitiligo DLQI (Dermatology Life Quality Index) scores are comparable to psoriasis and eczema. Depression and anxiety affect approximately 20-35% of vitiligo patients. Social stigma is particularly severe in South Asian and African cultural contexts. The psychological dimension requires acknowledgement and referral to psychological support where needed.

Koebner phenomenon — trauma triggers new lesions

The Koebner phenomenon in vitiligo: new white patches appearing at sites of skin trauma (friction, burns, cuts, scratches). This is an important counselling point — patients should be advised to avoid skin trauma (tight clothing, sunburn, abrasive skin treatments) to prevent new lesion development. The Koebner phenomenon also helps distinguish vitiligo from pityriasis versicolor (fungal hypopigmentation — no Koebner; spares palms/soles).

Key statistics

1-2%

global population prevalence of vitiligo — all ethnicities equally affected

WHO/ISDS

FDA July 2022

ruxolitinib cream (Opzelura) — first approved topical treatment for vitiligo

FDA 2022

~30%

patients achieving F-VASI75 (facial) at 24 weeks with ruxolitinib (TRuE-V trials)

NEJM 2022

50-75%

repigmentation rate with NB-UVB phototherapy (6-12 months, twice weekly)

Cochrane/BAD

20-35%

vitiligo patients have comorbid depression or anxiety

ISDS/Dermatology

Autoimmune

vitiligo association: thyroid disease (Hashimoto's, Graves'), type 1 diabetes, alopecia areata, pernicious anaemia

WHO/ISDS

Vitiligo treatment evidence — repigmentation rates by approach

Source: Cochrane/EDF/ISDS. NB-UVB most established; ruxolitinib cream new standard for topical; surgery for stable segmental.

Glossary of key terms

JAK-STAT pathway in vitiligo
Immunology/DermatologyIn vitiligo, activated CD8+ T-cells produce IFN-γ → IFN-γ activates JAK1/JAK2 signalling on keratinocytes and melanocytes → STAT1 phosphorylation → production of CXCL9 and CXCL10 → chemokine gradient attracting more CD8+ T-cells to skin → self-amplifying loop that destroys melanocytes. Ruxolitinib (JAK1/2 inhibitor) and baricitinib (JAK1/2 inhibitor) block this IFN-γ-JAK-CXCL10 pathway → breaking the amplification loop → stopping melanocyte destruction → allowing repigmentation from the hair follicle reservoir of melanocyte stem cells.

Melanocyte stem cell reservoir
Dermatology/RepigmentationRepigmentation in vitiligo occurs primarily from the outer root sheath of hair follicles — which contains a reservoir of melanocyte stem cells (MSCs) that are relatively protected from immune attack. This explains: (1) Why follicular repigmentation (peripilar macules — small pigmented dots around hair follicles) is the earliest sign of treatment response; (2) Why glabrous skin (palms, soles, lips, nipples — no hair follicles) is most resistant to repigmentation; (3) Why phototherapy (which activates MSC migration) works better on non-acral sites. Complete repigmentation requires migration and differentiation of MSCs across the depigmented epidermis.

NB-UVB phototherapy
Dermatology/WHONarrowband ultraviolet B (NB-UVB) phototherapy using 311-313nm wavelength: the most effective established treatment for widespread non-segmental vitiligo. Mechanism: suppresses T-cell activity in the skin; activates melanocyte proliferation and migration; stimulates melanocyte stem cells in hair follicles. Protocol: twice weekly sessions (minimum — 3× weekly ideal); starting dose determined by Fitzpatrick skin type and Minimal Erythema Dose (MED); incremental dose increases. Duration: 6-12 months minimum trial. Limitations: requires access to a phototherapy unit; time-consuming (multiple visits per week); less effective on acral sites (hands, feet, lips).

Ruxolitinib cream (Opzelura)
FDA 2022/IncyteA 1.5% cream formulation of ruxolitinib — a selective JAK1 and JAK2 inhibitor — for topical application to affected areas. Applied twice daily. FDA-approved for non-segmental vitiligo in adults and adolescents ≥12 years. TRuE-V1 and TRuE-V2 trials: randomised, double-blind, vehicle-controlled, 52 weeks. Primary endpoint (F-VASI75 — ≥75% improvement in facial vitiligo area score): approximately 30% ruxolitinib vs approximately 10% vehicle at 24 weeks. Systemic exposure is low (much lower than oral ruxolitinib). Adverse effects: application site acne; nasopharyngitis (systemic absorption sufficient to cause mild immune effects in some); potential for skin infections. Not for use on extensive body surface areas (>10%) due to systemic absorption risk.

Autoimmune associations
ISDS/ImmunologyNon-segmental vitiligo is associated with multiple other autoimmune conditions — reflecting shared genetic susceptibility (HLA-A*02:01; PTPN22; NLRP1; TYR; others) and a generally hyperactive adaptive immune system: Thyroid autoimmunity (Hashimoto's thyroiditis — most common association, approximately 15-20% of vitiligo patients; Graves' disease). Type 1 diabetes mellitus. Alopecia areata. Pernicious anaemia. Addison's disease (autoimmune adrenalitis). Inflammatory bowel disease. Psoriasis. Clinical implication: patients with vitiligo should have annual thyroid function + TFT autoantibodies; assess for other autoimmune conditions. First-degree relatives of vitiligo patients have elevated risk of autoimmune thyroid disease.

Pityriasis versicolor — the differential
DermatologyPityriasis (tinea) versicolor: superficial fungal infection (Malassezia furfur) causing hypopigmented (or hyperpigmented) macules — a common differential for vitiligo. Distinguishing features: pityriasis versicolor: involves trunk and upper arms predominantly; fine scale when scratched (Wood's lamp: yellow-gold fluorescence; vitiligo: bright white); responds to antifungal (ketoconazole shampoo, oral fluconazole); spores and hyphae on KOH scraping ("spaghetti and meatballs"). Vitiligo: no scale; no fluorescence change (Wood's lamp accentuates whiteness); palms/soles and mucosal surfaces can be involved; Koebner phenomenon; autoimmune associations.

Latest GMJ coverage

Articles will appear here as the archive grows.

Vitiligo

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company